BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. Its pipeline includes several drug candidates: BBO-8520, an orally bioavailable small molecule direct inhibitor currently in Phase I clinical trial for KRASG12C mutant non-small cell lung cancer; BBO-11818, an orally bioavailable pan-KRAS inhibitor in Phase I for KRAS G12D and G12V mutant cancers; and BBO-10203, an orally bioavailable small molecule in Phase I for HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. The company also develops other precision oncology assets for patients with tumors.

BridgeBio Oncology Therapeutics, Inc. is listed on the NasdaqGM exchange under the ticker symbol BBOT. Its securities trade in U.S. dollars (USD), reflecting its primary listing in the United States. The company is headquartered in South San Francisco, California, and operates within the U.S. market.

BridgeBio Oncology Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative small-molecule therapeutics for oncology indications, including cancers driven by KRAS mutations and HER2+ breast cancer. The company's research and development efforts are centered on precision medicine, targeting specific genetic alterations in tumors.

BridgeBio Oncology Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the U.S. market, as indicated by its country and region classification. Its clinical trials and development programs are conducted in the United States, focusing on patients with various cancers such as non-small cell lung cancer, breast cancer, and colorectal cancer.

BridgeBio Oncology Therapeutics' pipeline includes three key drug candidates. BBO-8520 is an orally bioavailable small molecule direct inhibitor targeting KRASG12C mutant non-small cell lung cancer, currently in Phase I clinical trials. BBO-11818 is an orally bioavailable pan-KRAS inhibitor in Phase I for KRAS G12D and G12V mutant cancers. BBO-10203 is an orally bioavailable small molecule in Phase I for HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. The company also develops additional precision oncology assets for patients with tumors.